01.23.15
Conatus Pharmaceuticals has selected Veeva Vault eTMF and Veeva Vault QualityDocs cloud applications for the management of clinical study and quality and development documentation, respectively.
Conatus, for its network of external partners across a number of sites worldwide, sought a paperless solution to provide a more efficient way for all parties to access content. With Vault eTMF and Vault QualityDocs, Conatus has a single source for verified, current documents, streamlining information-sharing across the enterprise.The company had previously been using a hybrid of paper and electronic document management processes to support the clinical study of its compound, Emricasan.
“To increase efficiency and enable our teams to focus on our core business, we wanted to outsource our key business applications – that’s what led us to Veeva. Easily configured to our specifications and continually updated, Vault ensures we are always working with the latest and most relevant technology without a large infrastructure investment or time drain,” said Conatus chief executive officer Steve Mento. “Our priority is developing drugs – not managing paper or upgrading technology. Vault helps us move faster and improve effectiveness by allowing us to collaborate easily, maintain the control we need in a regulated environment, and improve visibility.”
Conatus, for its network of external partners across a number of sites worldwide, sought a paperless solution to provide a more efficient way for all parties to access content. With Vault eTMF and Vault QualityDocs, Conatus has a single source for verified, current documents, streamlining information-sharing across the enterprise.The company had previously been using a hybrid of paper and electronic document management processes to support the clinical study of its compound, Emricasan.
“To increase efficiency and enable our teams to focus on our core business, we wanted to outsource our key business applications – that’s what led us to Veeva. Easily configured to our specifications and continually updated, Vault ensures we are always working with the latest and most relevant technology without a large infrastructure investment or time drain,” said Conatus chief executive officer Steve Mento. “Our priority is developing drugs – not managing paper or upgrading technology. Vault helps us move faster and improve effectiveness by allowing us to collaborate easily, maintain the control we need in a regulated environment, and improve visibility.”